Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2... von Franke, Klara, Foller, Susan, Rosero Moreno, Michele Estephania, Ali, Nalyan, Leistritz, Lutz, Leucht, Katharina, Grimm, Marc-Oliver

Volltext